Image-Guided Ablative Therapies for Lung Tumors by Chan, Joyce W.Y. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
125,000 140M
TOP 1%154
5,000
1Chapter
Image-Guided Ablative Therapies 
for Lung Tumors
Joyce W.Y. Chan, Rainbow W.H. Lau and Calvin S.H. Ng
Abstract
While the gold standard for early stage lung cancers is still surgical resection, 
many patients have comorbidities or suboptimal lung function making surgery 
unfavorable. At the same time, more and more small lung nodules are being inci-
dentally discovered on computer tomography (CT), leading to the discovery of 
pre-malignant or very early stage lung cancers without regional spread, which could 
probably be eradicated without anatomical surgical resection. Various ablative 
energies and technologies are available on the market, including radiofrequency 
ablation, microwave ablation, cryoablation, and less commonly laser ablation and 
irreversible electroporation. For each technology, the mechanism of action, advan-
tages, limitations, potential complications and evidence-based outcomes will be 
reviewed. Traditionally, these ablative therapies were done under CT guidance with 
percutaneous insertion of ablative probes. Recently, bronchoscopic ablation under 
ultrasound, CT, or electromagnetic navigation bronchoscopy guidance is gaining 
popularity due to improved navigation precision, reduced pleural-based complica-
tions, and providing a true “wound-less” option.
Keywords: radiofrequency ablation, microwave ablation, cryoablation, percutaneous 
ablation, bronchoscopic ablation, electromagnetic navigation bronchoscopy
1. Introduction
With the increasing availability of computer tomography (CT) scans and 
enlarging body of evidence for low-dose CT screening in high risk populations, a 
rising number of lung nodules are discovered incidentally. Many of them are small, 
sub-solid, and harbor pre-malignant or early stage cancers. Local therapies for 
these lesions are gaining evidence support, especially in patients with high surgical 
risks or decline surgery. Sublobar resection has been shown to confer similar 5-year 
survival rates, especially in older patients, tumor smaller than 2 cm, and pure bron-
choalveolar carcinoma [1–3]. Stereotactic body radiation therapy (SBRT) is targeted 
toward patients with stage I or II non-small cell lung carcinoma (NSCLC) without 
lymph node involvement and who are medically inoperable. SBRT has a local 
control rate of more than 80% in multiple retrospective series [4], and disease-free 
survival of 26% and overall survival of 40% at 4 years in a multicentre phase II 
study [5]. However, sublobar resection still carries surgical risks while SBRT has 
up to 22.3% risk of radiation pneumonitis and pneumonia. Since the early 2000s, 
percutaneous ablation of lung tumors has been attempted [6] following reports of 
efficacy of local ablation in liver cancers. The subsequent decade saw the blossom 
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of image-guided local ablative therapies of lung tumors, first with radiofrequency 
ablation (RFA), later with microwave ablation (MWA) and cryoablation. In this 
chapter, we discuss the preparation and procedure of lung ablative therapies, the 
various energy used, their pros and cons, evidence for safety and efficacy, and a 
glimpse into the future with a special section on bronchoscopic ablation.
2. Patient and nodule selection
Image-guided lung ablation is best suited for patients who have high surgical 
risks, either due to underlying medical comorbidities, or due to inadequate respira-
tory reserve, for instance significant chronic obstructive pulmonary disease (COPD) 
or previous contralateral lobectomy or pneumonectomy making intra-operative 
one-lung ventilation difficult. In general, there are no lower limits of lung function 
requirement for ablation candidates [7], but patients should be expected to tolerate 
sedation or general anesthesia at supine, lateral decubitus or semi-prone position 
for at least an hour. Contraindications for ablation include severe interstitial lung 
disease (ILD), where exacerbation of ILD may lead to severe pulmonary failure and 
death [8].
When ablation is intended for local control of early stage lung cancer, the tumor 
should ideally be small enough to be covered by the expected ablation zone with 
adequate margin, and there should be no nodal or extrathoracic metastasis based on 
pre-operative imaging. Ablation with palliative intent is best suited for lung cancers 
with tumor-related symptoms, for example pain and airway obstruction. Tumor 
size must be considered, and numerous lung ablation studies have demonstrated 
increased risk of local recurrence for increasing size of tumors, with cut-off of 2 cm 
[9] and 3 cm [10, 11] reported. In case of larger tumors, double ablation may be 
required, which either involves re-ablating in the same position, after pull-back of 
electrode, or after repositioning of electrode. Alternatively, ablation catheters with 
multiple electrodes can be used to generate a larger ablation zone.
Tumor location is also important to consider before submitting patient to 
thermal ablation. Nodules which are not suitable candidates for CT-guided biopsy 
are generally not recommended for percutaneous ablation, for example those 
shielded by the bony scapula, very close to diaphragm or hilar structures. Tumors 
located close to medium to large blood vessels are susceptible to heat-sink effects 
and ablation efficacy may be reduced. Ablation of tumors close to the apex or 
mediastinal structures may risk thermal injury to brachial plexus, phrenic nerve 
and adjacent organs such as the heart and esophagus, although hydro-dissection or 
artificial pneumothorax to protect surrounding structures have been reported with 
success [12].
3. Procedure and planning
Pre-procedure workup includes CT imaging ideally within 4 weeks of the 
planned ablation date. Patients were fasted overnight before ablation to reduce risk 
of sedation-induced nausea and aspiration. Anti-coagulation or anti-platelet medi-
cations were stopped as per regional guidelines for invasive procedures. Implantable 
cardiac devices like pacemakers or defibrillators are susceptible to interference from 
certain ablation modalities, and should be interrogated and programed by cardiac 
electrophysiologist to automatic pacing modes, or by placing a magnet over the 
device, while defibrillation should be turned off during ablation. Grounding pads 
should be placed to guide the flow of current away from the cardiac device and 
3Image-Guided Ablative Therapies for Lung Tumors
DOI: http://dx.doi.org/10.5772/intechopen.94216
electrodes should be inserted at least 5 cm away from pacemaker or defibrillator 
leads. External pacing and defibrillator system should be readily available in case of 
emergency.
Most ablation strategies are performed percutaneously, and nearly all are done 
under CT guidance. The great majority of ablation are performed with conscious 
sedation, while general anesthesia is reserved for pediatric patients or patients 
who cannot tolerate sedation alone, although some authors have reported higher 
feasibility rates and lower peri-procedural pain with general anesthesia [13]. For 
certain ablation energies, a reference electrode or grounding pad is necessary, which 
is attached to patient’s skin usually on the opposite chest wall or thigh. Initial scout 
CT images are acquired; the skin entry site is determined and cross-marked on the 
skin by laser lights from the CT gantry. Following sterile preparation and draping, 
local anesthesia is injected along the tract from skin to the level of pleura. A spinal 
needle is advanced according to the planned trajectory with CT and/or fluoroscopy 
guidance, which is then exchanged to the ablation electrode after confirmation of 
correct placement.
The aim of all ablation modalities is to create a zone of tissue necrosis that 
encompasses both the tumor and a margin of normal parenchyma surrounding it. 
The choice of electrode length, active tip length and the number of electrodes is 
determined by the size and location of tumor. The actual ablation zone size may 
differ from the predicted size. Factors include the heat-sink effect [14], which refers 
to the fact that medium to large blood vessels or airways carry heat away leading 
to asymmetrical or truncated ablation zones. Depending on the energy used, the 
lung’s conductivity, impedance and density also play a role in affecting the eventual 
ablation zone volume. In general, microwave is able to produce a larger ablation 
zone than radiofrequency due to its mechanism of energy deposition [15], with 
explanation detailed later in the chapter. After the initial ablation, a CT evaluation 
of ablation effect should be performed. In case of inadequate ablation volume, 
re-ablation with several overlapping ablation zones, or exchange to larger and more 
powerful electrodes can be performed.
After ablation and removal of electrode, CT images are acquired to evaluate 
technical success and rule out any complications, for example pneumothorax and 
bleeding. Patients are observed for 2–4 hours and a repeat chest x-ray confirms the 
absence of pneumothorax. Most patients are discharged the same day if no compli-
cations arise. Median length of stay was 1 day in a nation-wide review [16].
Figure 1. 
(A) CT scan shows a biopsy proven left upper lobe lung metastasis in a patient with stage III colonic cancer 
who was treated with colectomy and chemoradiation previously. (B) CT-guided radiofrequency ablation of the 
lung metastasis was performed with ablation catheter in-situ and an area of surrounding ground glass opacities 
(GGO). (C)The ablated area evolved into a denser GGO with central cavitation at 1 month after ablation. 
(D) CT scan at 6 months after ablation showed evolution of the ablated area into a smaller contracted scar 
with no signs of recurrence.
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Subsequent follow up required interval CT scans for evaluation of treatment 
response, usually every 3 months although no international guideline exists [17]. 
Typical early CT appearances following heat-based thermal ablation (eg. RFA, 
MWA) include ground glass opacities (GGO) or cavities, with or without soft tissue 
components. The GGO is typically concentric with three layers, the central consoli-
dation represents ablated tumor tissue, the middle layer of faint GGO represents 
necrotic surrounding parenchyma, and an outer rim of denser GGO contains con-
gested lung tissue and hemorrhage than may retain viability [17]. Cavitation, which 
is considered a positive response, is most likely to appear in the intermediate phase 
(1 week to 2 months after ablation). At 3 to 6 months post-ablation, the ablated area 
continues to involute and shrink down to a linear or nodular scar, or even a thin-
walled cavity. Enlarging ablation zone beyond 6 months is highly suggestive for 
tumor recurrence. Central enhancement >10 mm or > 15HU suggests progression of 
incompletely ablated disease on contrast CT scans [18], while increased metabolic 
Figure 3. 
(A) A cavity with soft tissue component surrounded by patchy ground-glass consolidations at 1 month after 
microwave ablation of a left upper lobe lung cancer. (B) Complete response as the ablation zone turned into 
a thin-walled cavity without soft tissue component at 6 months after ablation, which persisted with static 
appearance thereafter.
Figure 2. 
(A): At 2 weeks after microwave ablation of a small right lower lobe lung tumor, there was a larger- 
than-expected cavity noted in chest x-ray upon follow up. CT showed a large thick-walled cavity with central 
soft tissue likely representing necrotic lung and tumor tissue. There was no pneumothorax. (B) CT scan at 
3 months post-ablation showed reduction in size of the cavity and soft tissue component. (C) CT scan at 
6 months post-ablation showed disappearance of cavity and further reduction in overall size of the ablated 
area, now consisting of soft tissue density. (D) CT scan at 9 months post-ablation showed a contracted scar 
representing good treatment response.
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activity or new uptake inside the ablation zone beyond 2 months post-ablation are 
worrisome of recurrence on PET/CT scans [19]. Patients with local recurrence can 
undergo repeated ablation to improve local control. Figures 1–3 show the typical 
appearance of successfully ablated lung tumors over serial CT imagings. CT-guided 
ablation of centrally located metastasis can be combined with surgical resection 
of other more peripheral lung metastases as part of lung-preserving strategy, as 
illustrated in Figure 4.
4. Ablation energies
Ablation techniques can be divided into thermal or non-thermal ablations  
(e.g. irreversible electroporation). Among thermal ablations, heat-based techniques 
include radiofrequency ablation, microwave ablation and laser ablation, while cold-
based technique includes cryoablation. Table 1 shows the comparison of thermal 
ablation modalities in the lung.
Figure 4. 
(A) A 43 year old patient had curative resection of a hepatocellular carcinoma, but was found to have 5 lung 
metastases on surveillance CT, 3 of which in the right lower lobe (RLL) (as shown), and 2 more in the right 
middle lobe (not shown). The deepest lung metastasis in the RLL (*) would be difficult to palpate intra-
operatively, making wedge resection difficult. Patient was keen for lung-preserving treatment, thus a combined 
strategy of CT-guided ablation and surgical wedge resection was planned. (B) CT guided radiofrequency 
ablation of the deepest RLL lung metastasis was performed. (C) The ablation zone evolved into a well-
demarcated ground glass opacity with soft tissue component 2 weeks after ablation. (D) Wedge resection of the 
remaining 4 lung metastases located in peripheral right lower and middle lobe was performed with video-
assisted thoracoscopic surgery. CT scan at 3 months after ablation showed contraction of the ablation zone (#) 
and disappearance of the other 2 RLL lung metastases after surgery. (E) CT scan at 7 months after ablation 
showed further contraction of the ablated area. (F) CT scan at 1 year after ablation showed a small contracted 
lobulated scar remaining at the ablated area, and no recurrence of lung metastasis.
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4.1 Radiofrequency ablation (RFA)
Radiofrequency ablation is the most widely used ablative modality in the lung, 
and utilizes heat as a form of thermal ablation. Radiofrequency refers to a section in 
the electromagnetic spectrum with frequency ranging between 20 kHz to 30 MHz, 
but most clinically available devices function in the 375-500KHz range. A ground-
ing pad or reference electrode is required in RFA, while the active electrode placed 
inside the tumor is coupled to an RF generator. The RF generator establishes a voltage 
between the active electrode and reference electrode, producing electric field lines 
that oscillate with alternating current. At the area closest to the applicator, electrons 
collide with adjacent molecules under the influence of oscillating electric field, induc-
ing frictional heating [20]. Immediate cell death occurs at temperatures greater than 
60°C. RF electrodes have an internal thermocouple that measures the temperature at 
the tip. Charring and desiccation at the electrode increases impedance and reduces 
heat conduction, thus most commercially available electrodes are coupled with 
infusion pumps that pump cold saline to internally cool the electrode tip. Treatments 
usually range between 4 and 12 minutes, and RFA electrodes may be single-tip 
applicators or cluster electrodes.
Multiple RFA systems are commercially available (Boston Scientific, Watertown, 
MA, USA; StarBurst (RITA) Medical Systems, Mountain View, CA, USA; Cool-
Tip, Covidien, Boulder, CO, USA). The first two use a deployable radiofrequency 
array electrode with 4–16 small wires tines through a 14- to 17-gauge needle. The 
Radiofrequency 
ablation
Microwave Ablation Cryoablation
Mechanism of action Frictional heating 
from electron 
collisions under 
oscillating electric 
field
Frictional heating from 
rapidly realigning polar 
water molecules under 
oscillating electric field
Ultracold temperature 
when pressurized argon 
gas expands (Joule 
Thomson effect)
History of application 
in lung cancer
Since early 2000s Since mid 2000s Since mid 2000s
Temperature (°C) 60 to 100 Around 150 −20 to −40
Grounding pad Required Not required Not required
Ablation zone size Smaller Larger Larger
Dependence on 
impedance
Yes No No
Affected by tissue 
charring
Yes No No
Ablation time per 
ablation
Medium
(10–15 minutes)
Shortest
(2–10 minutes)
Longest
(25 minutes)
Visibility on CT/MRI Fair (concentric GGO) Fair (concentric GGO) Best (iceballs)
Heat sink effect Larger Smaller —
Preservation of 
bronchovascular 
structures
Fair Fair Best
Procedural pain Fair Less Least
GGO, ground glass opacity.
Table 1. 
Comparison between different modalities of lung cancer thermal ablation.
7Image-Guided Ablative Therapies for Lung Tumors
DOI: http://dx.doi.org/10.5772/intechopen.94216
third system consists of a single or triple cluster (3 electrodes spaced 5 mm apart) 
electrode perfused with saline, and a switching controller allow for simultaneous 
placement of up to three separate single electrodes to create a greater volume of 
thermocoagulation in a single application.
4.1.1 Efficacy of radiofrequency ablation
The local control and survival rates of RFA have been examined in a handful 
of non-randomized single-institutional series and a few multicenter trials. The 
RAPTURE study published in 2008 is a prospective, intention-to-treat, multicenter 
trial involving seven centres in Europe, USA and Australia [21]. It included 106 
patients with 183 biopsy-proven lung tumors, although there was a mixture of 
NSCLC and lung metastases. Technical success rate was 99%, and a confirmed 
complete response lasting at least 1 year was achieved in 88% of patients. For patients 
with NSCLC, overall survival was 70% at 1 year and 48% at 2 years, cancer-specific 
survival was 92% at 1 year and 73% at 2 years. Selecting those with stage 1 NSCLC, 
the 2-year overall survival was 75% and cancer-specific survival was 92%. More 
recently, another multicenter trial, the ALLIANCE Trial, was published in 2015 
[9]. The overall survival was 86.3% at one year and 69.8% at two years, while local 
recurrence-free rate was 68.9% at one year and 59.8% at two years.
Regarding long term efficacy, a retrospective study revealed that for stage I 
NSCLC, the overall survival rate was 36% and 27% at 3 and 5 years respectively 
[10]. In another prospective intention-to-treat study, the complete response rate 
was 59.3% at a mean follow-up of 47 months, with a mean local recurrence interval 
of 25.9 months [22]. Median overall survival and cancer-specific survival were 33.4 
and 41.4 months respectively, while cancer-specific actuarial survival was 59% at 
3 years and 40% at 5 years [22].
Tumor diameter was found to be a negative prognostic factor. The difference 
between survival curves associated with large (>3 cm) and small (<=3 cm) lung 
tumors was significant (p = 0.002, 10], and there was a trend toward better efficacy 
for tumors smaller than 2 cm in diameter (p = 0.066, 23]. Tumor size less than 2 cm 
was associated with a statistically significant improved survival of 83% at two years 
in the ALLIANCE Trial [9]. In another study, complete necrosis was attained in 
all tumors less than 3 cm but only in 23% of larger tumors, and the mean survival 
of patients with complete necrosis was significantly better than that with partial 
necrosis [11]. An ablation area of at least 4 times larger than initial tumor was 
reported to be predictive of complete ablation treatment [23].
To date, there are no properly powered prospective trials comparing one RFA 
system with another or comparing RFA with other treatment modalities. There has 
been a propensity-matched analysis comparing RFA and surgery for stage 1 NSCLC, 
and the mean survival duration of RFA group and surgery group was 33.2 +/− 7.9 and 
45.4 +/− 7.2 months respectively, although the difference is not statistically significant 
[24]. A large propensity-matched retrospective study comparing thermal ablation 
(mostly RFA) with SBRT using the National Cancer Database reported no significant 
difference in overall survival at a mean follow up of 52.4 months, however unplanned 
hospital readmission rates were high in the thermal ablation group [25]. In a systemic 
analysis and pooled review, the local control rate was significantly lower in the RFA 
group compared to SBRT, although the overall survival remained similar [26].
4.2 Microwave ablation (MWA)
Microwave ablation for lung tumors has been gaining increasing momentum 
since the mid-2000s. Microwave occupies a much higher frequency range in the 
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electromagnetic spectrum between 300 MHz to 300 GHz. Compared to radiofre-
quency, microwave energy is able to create a much larger zone of active heating due 
to broader deposition of energy. Clinically available microwave applicators gener-
ally operate in the 900-245 MHz range [27]. MWA directly heats tissue to lethal 
temperatures greater than 150°C through dielectric hysteresis, which is a process in 
which the polar water molecules realign with the oscillating electric field generating 
kinetic energy, which is then transferred to neighboring tissues [28]. Being com-
pletely independent from electrical conductance, microwave energy deposition is 
less susceptible to tissue impedance, and is able to produce faster, larger and more 
predictable ablation zones than RFA [15]. The aerated lung has a relatively high 
impedance among all solid organs, thus making MWA a better modality than RFA 
in lungs [15, 29]. Heat-sink effect is also smaller with microwave [28].
There are 7 microwave systems commercially available in the United States 
and Europe, using either 915 MHz or 2450 MHz generators [30]. The antennae 
are generally straight, ranging from 14 to 17 gauge, with varying active tips of 
0.6–4.0 cm in length. Five out of seven systems require perfusion of antenna shaft 
with room-temperature fluid or carbon dioxide to reduce conductive heating of the 
non-active portion of the antennae, which protects the skin and other tissues from 
thermal damage.
4.2.1 Efficacy of microwave ablation
The majority of evidence supporting the efficacy of MWA comes from retro-
spective data. The earlier studies reported an actuarial survival of 65% at 1 year, 
55% at 2 years and 45% at 3 years, while cancer-specific survival was 83%, 73% and 
61% at 1, 2 and 3 years respectively [31]. A more recent retrospective study reported 
cancer-specific survival of 69%, 54% and 49% at 1, 2 and 3 years respectively, and 
the mean survival was 27.8 months [32]. Local control rate was 84.4% at a mean 
follow-up of 446 days in another retrospective series [33]. A larger retrospective 
review of 108 patients reported that the median time to tumor recurrence was 
62 months, and recurrence rates were 22%, 36% and 44% at 1, 2 and 3 years respec-
tively [34]. It should be noted that the majority of the studies include both primary 
and secondary lung tumors, and results for NSCLC may not be separately reported. 
Longer term results were reported in a study involving large NSCLC (mean tumor 
size of 5.0+/− 1.8 cm). Owing to the larger tumor size, only 44.6% of cases achieved 
complete tumor ablation after first ablation, and 18.5% required a re-do MWA 
session. The 3- and 5-year cancer-specific survival rates were 42.1% and 30.0% 
respectively, and the median cancer-specific survival was 25 months [35].
Similar to RFA, tumor size is associated with poorer prognosis. For every 
millimeter increase in tumor maximal diameter, the odds of not attaining 
technical success increased by 7% [34]. Tumor size >4 cm is a significant predic-
tor for local tumor progression and poorer survival [35]. Recurrence rate was 
17% for tumors smaller than 3 cm, and increased to 31% for those greater than 
3 cm [34]. A risk-factor analysis demonstrated that local tumor progression was 
significantly correlated with tumor diameter of more than 15.5 mm, irregular 
shape of index tumor, pleural contact and low energy deployed per unit volume 
of index tumor [36]. On the other hand, cavitation was associated with reduced 
cancer-specific mortality [31].
Again, there are no prospective studies comparing one MWA system with 
another, or with other modalities. There was a propensity-score matched analysis 
comparing MWA with lobectomy for stage I NSCLC, which reported no significant 
difference in overall survival and disease free survival (1,3 and 5-year disease free 
survival of 98.1%, 79.6% and 37.0% for MWA group and 98.1%, 81.5% and 29.6% 
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for lobectomy group) [37]. The complication rate in MWA group was significantly 
lower than lobectomy group (p = 0.008). However, the power of this study is 
undermined by the relatively poor results in lobectomy group when compared to 
international standard, probably due to poor patient premorbid. In a best evidence 
topic review, the best available evidence for MWA (7 studies) was compared to 
that for SBRT (5 studies) [38]. The 3-year survival was 29.2–84.7% for MWA and 
42.7–63.5% for SBRT, while the median survival was 35–60 months for MWA and 
32.6–48 months for SBRT. The authors concluded that MWA appears comparable 
to SBRT in terms of local control and survival rates. In the randomized controlled 
LUMIRA trial, 52 patients with stage IV lung tumors were recruited, and there was 
no significant difference in survival between the MWA group and RFA group, but 
MWA was found to produce less intraprocedural pain and a more significant reduc-
tion in tumor mass [39].
4.3 Percutaneous Cryoablation
Cryoablation makes use of the Joule-Thomson effect by distributing pressured 
argon gas to an area of lower pressure and reaching ultracold temperatures when 
the gas expands [40]. As low as −140°C can be achieved, although living tissue 
destruction already happens at −40°C. Cryogenic destruction occurs via a number 
of mechanisms, including protein denaturation, cell rupture due to osmotic shifts, 
and tissue ischemia from microvascular thrombosis [41]. Meanwhile, the term 
“cryosurgery” includes cryoablation performed through endobronchial, direct 
intrathoracic or percutaneous routes.
Traditionally, each cryoablation consists of a dual freeze cycle, involving a 
10-minute freeze, followed by 8-minute helium thaw and another 10-minute freeze. 
Early animal models suggest that air leaks and bleeding could be reduced with this 
protocol [42]. Current commercially available cryoablation devices (for example 
Cryocare CS® system, Endocare, Irvine, CA, USA) use a faster cycle of 3-minute 
freeze, 3-minute thaw, 7-minute freeze, 7-minute thaw and a final 5-minute freeze. 
These systems allow placement of 1–10 individual 1.5–2.4 mm diameter cryoprobes, 
and one freeze–thaw–freeze cycle at a single probe position usually suffice. The 
faster cycle produces interstitial fluid in adjacent lung tissue and improves margin 
control. Radiologically, a visible “ice ball” and surrounding edematous changes can 
be seen on CT and serve as an estimation of ablation zone. The true volume of tissue 
necrosis has been shown to be 3-7 mm from the ice-ball edge [43], and should be 
taken into consideration when determining cytotoxic ice margin clearance.
Compared with heat-based thermoablation like RFA and MWA, cryoablation 
has the advantage of larger ablation volumes, availability of multiple applicators, 
a highly visible ablation zone (a clearly defined ice ball as opposed to concentric 
ground glass opacities in RFA or microwave), and less pain due to analgesic effect 
of freezing [44]. Another benefit is its safety near vasculature or bronchi due to 
the ability to preserve collagenous tissue and cellular architecture in frozen tissue 
[45]. Disadvantages of cryoablation include a longer procedural time (25 minutes 
per freeze–thaw–freeze cycle compared to roughly 5 to 10 minutes per ablation in 
MWA) and a higher incidence of pneumothorax up to 62% [46]. The latter can be 
tackled with fibrin glue tract coagulation or radiofrequency thermocoagulation of 
needle tract provided by one of the cryoablation systems.
4.3.1 Efficacy of Cryoablation
A retrospective review of 25 stage I NSCLC treated with cryoablation reported 
3-year overall survival of 88% and mean overall survival of 62+/−4 months [47]. 
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Another study involving 27 cryoablated stage I NSCLC demonstrated 3-year sur-
vival of 77%, 3-year cancer-specific survival of 90.2% and cancer-free survival of 
45.6% [48]. In a study comprising of cryoablation of both primary and secondary 
lung tumors, the 1-, 2- and 3-year local progression free rates were reported to 
be 80.4%, 69.0% and 67.7% respectively [49]. In a long-term analysis of 47 stage 
I NSCLC treated with cryoablation, the 5-year cancer-specific survival rate was 
56.6+/−16.5% and 5-year progression free survival rate was 87.9+/−9% [50]. There 
were two randomized controlled trials, the ECLIPSE trial [51] and SOLSTICE trial 
[52], evaluating cryoablation of metastatic lung tumors, which report favorable 
safety and efficacy, but are out of the scope of this chapter.
Cryoablation has been performed for stage IV lung cancer for palliation of 
symptoms. In a comparative study between cryoablation and palliative treatment 
alone, the overall survival of the cryoablation group was significantly longer, with 
median survival of 14 months compared to 7 months [53]. The same group has 
performed cryosurgery in various stages of NSCLC yielding an overall survival of 
64%, 45% and 32% at 1, 2 and 3 years respectively [54].
Few studies have compared cryoablation with other treatment modalities. In 64 
patients with stage I NSCLC deemed medically unfit for lobectomy, 25 were treated 
with sublobar resection, 12 with RFA and 27 with cryoablation. The 3-year survival 
rate was similar for the three groups (87.1% for sublobar resection, 87.5% for RFA 
and 77% for cryoablation) [48]. In a comparative study for stage IIIB or IV NSCLC 
treated with cryoablation or MWA, the overall survival and progression-free sur-
vival were similar for tumors ≤3 cm in diameter, but were poorer in tumors greater 
than 3 cm which are treated with cryoablation [44].
4.4 Percutaneous laser ablation
Laser ablation is a thermal technique where light energy is converted into heat by 
interaction with sources such as an Nd: YAG laser. Typically, energy is transmitted 
through a flexible fiberoptic cable which is percutaneously inserted into the lung 
through an outer sheath. Cooling of the fiberoptic cable enables greater energy 
deposition and a 50 percent increase in size of thermocoagulation [55], as the size 
of ablation zone is limited by tissue carbonization near the applicator. To date, 
there have been limited reports on the efficacy of laser ablation in humans [56]. A 
long term analysis of laser ablation for lung metastases reported 1-, 3- and 5-year 
survival of 81%, 44% and 27% respectively [57], with a relatively high rate of 
pneumothorax (38%). No data is available for primary lung cancers.
4.5 Irreversible electroporation (IRE)
Electroporation is a phenomenon in which cell membrane permeability to ions 
and macromolecules is increased by exposure to high voltage electric pulses. It 
can be reversible or irreversible, with the latter leading to cell death from loss of 
homeostasis and osmotic effects. Since IRE is a non-thermal ablation modality, its 
theoretical advantage includes overcoming the heat-sink effect [58] and preserva-
tion of structural integrity of nearby bronchovascular structures [59]. Although 
there have been reports on its efficacy in animal models [60] and in other organs 
such as the liver [61], there were few reports on its use in human lungs [62]. In fact, 
in the multicenter phase II ALICE trial for treatment of primary and secondary lung 
malignancies, IRE failed to meet the expected efficacy and the trial was terminated 
prematurely after inclusion of 23 patients, in which 61% showed progressive disease 
[63]. The disappointing results may be explained by high differences in electric 
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conductivity between normal lung parenchyma and tumor tissue. Of note, needle 
tract seeding happened in 13% of cases.
5. Safety and complications of percutaneous ablation
Percutaneous ablation of lung tumors is generally considered safe. A list of 
potential complications is presented in Table 2. In a nationwide analysis of 3344 
patients who underwent percutaneous lung ablation in the United States [16], 
in-hospital mortality was 1.3%, and patients with more comorbidities (Charlson 
comorbidity index score ≥ 4) was associated with significantly higher mortality. The 
most common complication was pneumothorax (38.4%), followed by pneumonia 
(5.7%) and effusion (4.0%). In a Japanese review of 1000 RFA sessions [64], there 
was a 0.4% procedure-related mortality, of which three died of interstitial pneumo-
nia and another died of hemothorax. Major complication rate was 9.8%, consisting 
of 2.3% aseptic pleuritis, 1.9% pneumonia, 1.6% lung abscess (Figure 5), 1.6% 
pneumothorax requiring pleural sclerosis, 0.4% bronchopleural fistula and 0.3% 
brachial nerve injury. Previous radiotherapy and age were significant risk factors for 
pneumonia, as were emphysema for lung abscess, and platelet count and tumor size 
for bleeding [64].
Pneumothorax occurs as a result of pleural puncture by the ablation catheter lead-
ing to air leak. Hence, unlike standard lung biopsy technique, in which the shortest 
path to tumor is preferred, some operators advocated a longer distance between pleura 
puncture site and tumor is more desirable for ablation. An indirect approach that 
leaves an unablated tract of at least 2 cm of normal lung is preferable [29], because 
Complications Treatment/remarks
Pneumothorax 3.5–54% (Up to 10% 
delayed pneumothorax)
Only 6–29% require chest tube insertion
Pleural effusion/aseptic 
pleuritis
2.3–19% Only a minority require drainage
Bleeding 1.6–18% Rarely require emergency arterial embolization 
or surgery
Pneumonia 1.8% Antibiotics
Lung abscess 1.6% Antibiotics, drainage
Bronchopleural fistula 0.4–0.6% Prolonged chest tube drainage, chemical 
pleurodesis, endobronchial valves/
embolization
Needle tract seeding 0.3–0.7% Associated with biopsy prior to RFA
Thermal injury to 
nearby structures
0.3–0.5% (brachial 
plexus)
1.3% (phrenic nerve)
0.1% (diaphragm)
Phrenic nerve injury can lead to significant 
reduction in vital capacity and referred pain to 
shoulder
Pneumonitis 0.4% Pulse steroid
Pulmonary artery 
pseudoaneurysm
0.2% Transcatheter coil embolization
Systemic air embolism Very rare Hyperbaric oxygen
Table 2. 
Complications following thermal ablation in the lung.
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Figure 7. 
(A) A patient with right lower lobe lung cancer was treated with CT-guided microwave ablation, but 
complicated by persistent air leak for 2 weeks despite chest drain insertion. CT scan showed a moderate right 
pneumothorax and an area of ground glass opacity in the anterior right lower lobe representing the ablation 
zone. (B) CT scan performed at 3 weeks after ablation demonstrated a bronchopleural fistula (yellow arrow) 
joining a lobar bronchus to the pleural space through the ablated needle tract.
Figure 5. 
A small pneumothorax and a large cavity with soft tissue content at 2 weeks after microwave ablation of a 
left upper lobe lung tumor. If the patient had fever and air-fluid level was seen in the cavity, a suspicion for 
lung abscess should be raised, and the abscess should be drained with contents sent for culture and intravenous 
antibiotics should be commenced.
Figure 6. 
(A) A large right pneumothorax immediately after CT-guided radiofrequency ablation of a right lower lobe 
lung cancer. (B) Shows the lung re-expands after right chest drain insertion in the same patient.
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unablated pleura contracts less and heals quicker. Emphysema is the most significant 
risk factor for pneumothorax in multiple studies [65, 66]. Other risk factors include 
male gender, no previous lung surgery, high number of tumors ablated, advanced 
age, and traversal of major fissure by electrode [67]. The rate of pneumothorax 
ranges from 3.5–54%, but only 6–29% required chest tube placement [68] (Figure 6). 
Delayed pneumothorax could occur in up to 10% of cases [69, 70]. Around 0.4–0.6% 
of all patients develop bronchopleural fistula [64, 71] leading to intractable pneu-
mothorax not resolving with chest drainage (Figure 7). Treatment strategies include 
repeated chemical pleurodesis, placement of endobronchial valves (Figure 8), and 
bronchoscopic embolization of relevant fistulae [68].
Aseptic pleuritis and pleural effusion is postulated to be due to ablation zone 
reaching pleura leading of pleural inflammation, and is associated with higher 
Figure 8. 
Resolution of pneumothorax after implantation of an endobronchial valve (faint metallic shadow surrounded 
by yellow arrows) for bronchopleural fistula. This is the same patient as Figure 7 And the ablation zone is 
marked by (*) on this chest x-ray.
Figure 9. 
(A) Moderate right pleural effusion that has accumulated for 3 days following CT-guided microwave ablation 
of a right lower lobe lung tumor. The patient had low grade fever and complained of shortness of breath. (B) 
partial drainage of the effusion by a medium bore chest drain. The pleural fluid was exudative but sterile, and 
the patient was discharged home after a course of antibiotics and complete drainage of the effusion.
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Figure 10. 
The set-up for microwave ablation of lung nodules under electromagnetic navigation bronchoscopy (ENB) is 
shown. Within the hybrid theater, the patient lies supine and is intubated with single lumen endotracheal tube. 
With the help of navigation software like SuperDimension™ (@), and fine adjustment of position with cone-
beam CT (#), the target lung lesion is localized with a ENB bronchoscope. The microwave ablation catheter is 
inserted through the bronchoscope into the lung tumor, which is then connected to the microwave generator (*). 
The yellow arrow is pointing to the external part of microwave ablation catheter.
pleural temperatures [72]. Repeated punctures and previous systemic chemo-
therapy were significant risk factors [64]. Aseptic pleuritis gives rise to pleuritic 
pain, but most resolve spontaneously. Only a minority of pleural effusion required 
drainage (Figure 9).
The incidence of hemoptysis after percutaneous RFA is 3–9% [68], while the 
incidence of all forms of hemorrhage is approximately double that rate. Risk factors 
for intraparenchymal hemorrhage include basal and middle lung zone lesions, needle 
track traversing lung parenchyma by more than 2.5 cm, electrode traversing pulmo-
nary vessels and the use of multi-tined electrodes [73]. Although most hemorrhages 
are self-limiting, rarely ablation injury to intercostal artery may occur leading to 
massive bleeding [68].
6. Bronchoscopic ablation techniques
Most of the thermal ablative techniques in literature involved percutaneous 
placement of electrodes. Since 2010, a Japanese group pioneered a bronchoscopy-
guided cooled RFA technique for lung tumors in humans [74, 75], followed by a 
Chinese group using electromagnetic navigation bronchoscopy (ENB) guidance 
[76]. Compared to percutaneous approach, a major advantage of bronchoscopic 
ablation is lack of pleural puncture, and hence fewer pleural-based complications. 
The Japanese group reported no pneumothorax, bronchopleural fistula nor pleural 
effusion in 28 cases of bronchoscopic RFA [75], while the rate of pneumothorax for 
percutaneous ablation ranges from 3.5–54% as mentioned above. Bronchoscopic 
ablation also eliminates the risk of needle tract seeding. Another edge of broncho-
scopic ablation is its ability to reach certain regions of lung which are otherwise 
difficult or dangerous for percutaneous access, for instance areas near mediastinal 
pleura, diaphragm, lung apex, or areas shielded by scapula.
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With evidence of safety and technical success of bronchoscopic ablation in 
animal models [77], and the above-mentioned advantages in mind, the author’s 
institute is one of the first to perform ENB-guided microwave ablation on patients 
in the hybrid operating room (Figure 10). Navigation precision has been much 
improved following the advent of ENB with the help of navigation systems 
like SuperDimension™ (Covidien, Plymouth, MN, USA) (Figures 11 and 12), 
supplemented by position confirmation by fluoroscopy and cone beam CT. The 
microwave catheter (Emprint™ Ablation Catheter with Thermosphere™ tech-
nology, Covidien, Plymouth, MN, USA) is inserted within the lung tumor via 
bronchoscopy and ablated for up to 10 minutes per burn (Figure 13). Since early 
Figure 11. 
The planned navigation pathway (pink) from trachea to the target lung lesion in left upper lobe with the help 
of navigation software like SuperDimension™.
Figure 12. 
The SuperDimension™ software allows multiple views to guide navigation to a target lung lesion (green ball). 
The upper left panel shows the navigation pathway (pink) in virtual bronchoscopy view, while the lower 
left panel shows it in 3D map view. On the right side panel, the Centre of the target lung lesion is shown to be 
0.8 cm from the tip of the locatable guide.
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2019, we have performed 45 cases with 100% technical success rate. Similar to 
percutaneous approach, the median length of stay was 1 day only. Only 2 patients 
(4.4%) developed pneumothorax requiring chest drainage. Post-ablation reaction 
and fever occurred in 8.9%, minor hemoptysis or hemorrhage in 4.4%, and pleural 
effusion in 2.2%. As of the time of writing, there was no progressive disease at a 
mean follow up of 290 days. We believe that bronchoscopic ablation represents 
the future for lung cancer ablation as it offers a truly wound-less option with likely 
fewer complications.
7. Conclusions
Image-guided ablative therapy is an important armamentarium in the treat-
ment of lung cancers, either for early stage lung cancers in patients who are 
medically inoperable or refuse surgery, or for palliation of late stage lung cancers. 
Radiofrequency ablation is the most studied modality with a large body of evidence 
supporting its safety and efficacy, with comparable outcomes to sublobar resec-
tions and stereotactic radiation therapy in select patients. Nonetheless, microwave 
ablation is quickly catching up in popularity due to its superior properties over RFA. 
Traditionally, lung ablation was performed percutaneously, but the latest develop-
ment of bronchoscopic ablation techniques are promising and may drive the future 
of lung cancer ablation research.
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Figure 13. 
(A) The target lung lesion (yellow tracing) in 3 axes on CT before bronchoscopic microwave ablation. The 
green, red and blue ovals mark the expected ablation zone margins. (B) The post-ablation appearance of the 
same lung nodule. The lung tumor has been encompassed in the ablation zone, represented by ground-glass 
opacities.
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